Navigation Links
Zyngenia, Inc. Raises $10 Million in Series A Funding
Date:11/4/2009

ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, today announced that it has secured $10 million in Series A funding from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to create novel, multi-specific antibody-like molecules that address two or more biological targets with a single agent. The company will initially focus on various cancers and autoimmune diseases.

"Zyngenia's technology platform, developed by Carlos Barbas of The Scripps Institute, is very compelling due to its ability to create biologics that are single protein-combination therapeutics in a manner that is likely to be scientifically, medically, and economically transforming," said Peter Kiener, D.Phil., Zyngenia Chief Executive Officer. "With financial support from NEA, we are poised to take a leadership role in the development of multi-specific biologic therapies."

In previous positions at MedImmune and Bristol-Myers Squibb (BMS), Dr. Kiener gained extensive experience in both biologics and small molecule drug discovery across oncology, immunology, infectious disease and other therapeutic areas. During eight years at MedImmune, most recently as Executive Vice President and Head of Research and Development, Dr. Kiener helped to build industry-leading protein and antibody engineering capabilities and oversaw the submission of numerous INDs and BLAs. Dr. Kiener was also responsible for the integration of both the protein/antibody engineering company Cambridge Antibody Technology and the B-cell biologics company Cellective Therapeutics into MedImmune. Prior to joining MedImmune, Dr. Kiener spent 18 years with Bristol-Myers Squibb's Pharmaceutical Research Division.

Carlos F. Barbas, III, Ph.D., Zyngenia's Chief Scientific Officer, is Professor and Chair of the Skaggs Institut
'/>"/>

SOURCE Zyngenia, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. Enobia Pharma Raises $40.1 Million Series B Financing
3. Cardiosolutions Raises $7 Million for Spacer Technology to Mitigate Mitral Regurgitation
4. MannKind Corporation Raises $250 Million in Self Managed Registered Direct Offerings of Common Stock
5. VisEn Medical Raises $7 Million in Series B Financing
6. Thermo Fisher Scientific Reports Record Third Quarter Revenues and Adjusted EPS and Raises Full-Year Guidance
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Antibody Engineering Company f-star Raises EUR 3.0 Million in a Second Closing of its Series A Financing Round From Novo A/S
9. Perrigo Announces Final FDA Approval of Dexcels OTC Omeprazole; Raises Full Year Earnings Guidance
10. Anesiva Raises $45 Million in Common Stock Offering
11. Follica Raises $5.5 M To Advance New Treatment for Androgenetic Alopecia Into the Clinic

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2009)...t at the National Institute of Standards and Techn... inexpensive method for detecting and measuring el...ins, invisible spoilage in food or pesticides dist...thod is more sensitive than conventional technique...re polarlike water molecules, having distinct elec...
(Date:11/18/2009)...ts at Queen,s University Belfast are developing ne...ugs which will help in the fight against the threa...pecial gel pads to ,swipe, an individual or crime ... a scanning instrument that can detect the presenc...ter, faster decisions to be made in response to te...
(Date:11/18/2009)... IRVINE, Calif., Nov. 18 ...CO-Oximetry(TM) and Measure-Through Motion and Low...on, France-based Uni.H.A., one of the largest heal...nce, has signed a multi-year purchasing agreement ...ters. The agreement offers preferred contract pri...
(Date:11/18/2009)...MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - ... life sciences product development company that id...sing cancer-related products at various stages of ...valuating nimotuzumab were presented today in a po...and Cancer Therapeutics conference in Boston, Mass...
Breaking Biology Technology:Prototype NIST method detects and measures elusive hazards 2New technology detects chemical weapons in seconds 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 2Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 3Uni.H.A. in France Signs Purchasing Agreement for Masimo SET(R) Pulse Oximetry Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3
... Histology, Biomarkers and Non-Invasive Imaging to...ct on Vascular Inflammation , , SAN FRANCISCO, ...), a biotechnology company focused on the developm...ar and metabolic disease, today announced that it ...al of its lead drug, VIA-2291 in patients who have...
...delphia area-based probiotics firm Kibow Biotech w...s invited to present at the BIO 2009 Company Forum... GA on Tuesday, May 19. BIO is the world,s largest...usiness development and communications services fo...s worldwide. BIO members are involved in the resea...
...c. (CTI) (Nasdaq and MTA: CTIC) management will pr...the Georgia International Convention Center in Atl... Room 311 of Building A, Level 3. , , , ..., CTI Presentation: Tuesday,... PM Central European/7:40 AM Pacific, ...
Other Biology Technology:VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 2VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 3VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 4VIA Pharmaceuticals Announces Complete Enrollment in FDG-PET Phase 2 Study of VIA-2291 in Cardiovascular Patients 5Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 2Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 3Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World 4
(Date:11/19/2009)...HACA, N.Y. - A new study of maize has identified t...ble portions of the genome. New techniques may all...riation to identify desirable traits and create ne..., Publishing in the Nov. 19 issue of Science , ... at Cornell, have identified the first map of hapl...
(Date:11/19/2009)... JOLLA, CA November 19, 2009 A team led by scient...ered a direct link between insulina hormone long a...such as diabetesand core body temperature. While m...ts discovery in the 1920s, this is the first time ...process of temperature regulation. , The paper w...
(Date:11/19/2009)...AMPAIGN, Ill. A new statistical technique develop...lows scientists to scan a genome for specific gene...dge of the relevant transcription factors. The tec...he mouse genome and the fruit fly genome. , "Our ...n other approaches, and is especially useful for i...
Breaking Biology News(10 mins):New map of variation in maize genetics holds promise for developing new varieties 2Scripps research scientists find new link between insulin and core body temperature 2Scripps research scientists find new link between insulin and core body temperature 3Scripps research scientists find new link between insulin and core body temperature 4Technique finds gene regulatory sites without knowledge of regulators 2Canadian Cardiovascular Society recognizes trailblazing work by U of Alberta heart researcher 59970 1Canadian Cardiovascular Society recognizes trailblazing work by U of Alberta heart researcher 59970 2Canadian Cardiovascular Society recognizes trailblazing work by U of Alberta heart researcher 59970 3Scientists Discover Gene Key to Human Speech 59968 1Scientists Discover Gene Key to Human Speech 59968 2Red grape skin extract could be new treatment for sickle cell disease patients 59966 1Red grape skin extract could be new treatment for sickle cell disease patients 59966 2
...Argonne National Laboratory have found elevated am...Century composer Ludwig von Beethoven, consistent ...ead found in his hair. These results confirm the c... , The bone fragments, confirmed by DNA testing to...X-rays from the Advanced Photon Source at Argonne,...
...s are published, including a new book entitled Th...arch articles in the journal Genome Research . T...n by Nature of a high-quality draft sequence of ...rchers and the public with informative resources a...cs has entered a period of unprecedented growth an...
... has the important task of nourishing the plant em...n flowering plants, there is a complicated double-...and endosperm. , They develop together into matur...between the two parts of the seeds, has been uncle...stitute for Plant Breeding Research and the Univer...
Other Biology News:Argonne researchers confirm lead in Beethoven's illness 2Argonne researchers confirm lead in Beethoven's illness 3Dog genome sequenced 2Dog genome sequenced 3Dog genome sequenced 4The secret love life of plants 2
...), 22K is useful for investigating plant organ fun...icroarray contains content derived from the ATH1 v... (TIGR) and represents 21,500 genes. Kit conta...g an identical 22K oligonucleotide microarray prin...
...llions of dollars worldwide, pharmaceutical manufa...e to reduce expensive rework costs. In tablet prod...s is known to impact important quality parameters ...nd hardness. However, to date there have been no c...
... a rapid and efficient immunoprecipitation and elu...recipitation is performed with ANTI-FLAG-M2 affini...body covalently attached to agarose resin. The use...FLAG-tagged proteins without the need for prelimin...
... detection, isolation, differentiation and/or coun...orms from other Gram-negative bacteria. ,The detec...nal biochemical tests, no sterilization during pre...ity and sensitivity than with the conventional med...
Biology Products: